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Abstract
Background: To speed up the evaluation of new therapies, the multi-arm, multi-stage trial design
was suggested previously by the authors.
Methods: In this paper, we evaluate the performance of the two-stage, multi-arm design using four
cancer trials conducted at the MRC CTU. The performance of the design at fictitious interim
analyses is assessed using a conditional bootstrap approach.
Results: Two main aims are addressed: the error rate of correctly carrying on/stopping the trial
at an interim analysis as well as quantifying the gains in terms of resources by employing this design.
Furthermore, we make suggestions for the best timing of this interim analysis.
Conclusion: Multi-arm, multi-stage trials are an effective way of speeding up the therapy
evaluation process. The design performs well in terms of the type I and II error rates.
Background
Multi-arm, multi-stage (MAMS) trials employing an inter-
mediate outcome in the early stages of a multi-stage trial
with multiple research arms have been proposed as means
of speeding up the evaluation of new therapies [1]. The
design itself is based on discontinuing randomisation to
'poor' treatments at an early stage, and allowing through
to the further stages only those treatments which show a
predefined degree of advantage against the control treat-
ment. In the early stages, the experimental arms are com-
pared pairwise with the control according to an
intermediate outcome measure. The advantage of using
intermediate endpoints at interim analyses in general has
been examined by Goldman et al. in simulation studies
[2]. Treatment arms that survive this comparison then
enter a further stage of patient accrual which ultimately
culminates in pairwise comparisons against the control
based on the primary endpoint. Thus, the trial is only
stopped for lack of benefit, not evidence of a benefit as in
many other designs [3,4]. A major issue for these designs
is to assess their operating characteristics and in particular
to preserve pairwise power at each stage and for the trial
overall, whereby power in the second stage is conditional
upon a treatment jumping the 'hurdle' at the first stage
analysis.
The aim of this study was to determine whether trials
which had been conducted as standard parallel group tri-
als would have benefitted from being conducted as a
multi-stage trial using the MAMS methodology. To
achieve this, data from four different trials was used. There
were two main objectives to this study: Firstly to assess
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been correctly carried on/stopped at interim analyses and
secondly to quantify gains made in terms of use of
resources by employing the MAMS methodology. Hence,
we were concerned about the error rate at the first stage
given a particular outcome at the final stage analysis. An
error is defined in this context as either stopping early a
trial where the final analysis would have shown an effect
or carrying on a trial at the interim analysis when the final
analysis would have shown no evidence of an effect. To
accomplish this, a series of analyses of the intermediate
outcome measure were mimicked for each of the trials
using both the original trial data and bootstrapped sam-
ples from the data [5].
Methods
Trials
Four trials comparing treatments in different cancer sites
were included in the analysis. Two of these had a positive
outcome in favour of the new therapy, one was 'negative',
showing no evidence of a difference between research and
control arm, and one was a multi-arm trial with 'negative'
and 'positive' results.
The first trial, RE01, showed considerable evidence of a
treatment difference in terms of overall survival [6]. In this
trial patients with metastatic renal cancer were ran-
domised equally to subcutaneous alpha-interferon
(experimental) or oral medroxyprogesterone acetate (con-
trol). A comparison of overall survival in the two groups
showed a 28% reduction in the mortality rate in the
alpha-interferon group (Hazard ratio = 0.72, 95% Confi-
dence Interval 0.55–0.94). This trial used a triangular
sequential design which allowed for early stopping as
soon as results were conclusive.
Two trials in ovarian cancer were also re-analysed. In
ICON3 [7], patients were randomised 1:2 to a research
arm of paclitaxel plus carboplatin against a control arm of
single agent carboplatin or CAP (cyclophosphamide, dox-
orubicin, cisplatin). The trial showed no evidence of an
improvement of the experimental against the control arm
(HR = 0.98, 95% Confidence interval 0.86 – 1.10). The
second ovarian cancer trial, ICON4 [8] was designed to
assess whether giving paclitaxel with platinum-based
chemotherapy would benefit women with relapsed 'plati-
num-sensitive' ovarian cancer more than conventional
platinum-based chemotherapy. The trial showed a
marked improvement of the experimental over the con-
trol treatment (HR = 0.78, 95% Confidence interval 0.65
– 0.95).
Finally, the multi-arm trial FOCUS [9] in poor prognosis
advanced colorectal cancer was also re-analysed. In this
trial patients were randomised 2:1:1:1:1 to five treatment
plans A, B, C, D and E. Regimen A (control) comprised
single-agent fluorouracil until clinical disease progres-
sion, then single-agent irinotecan. B and C were fluorour-
acil then, respectively, fluorouracil/irinotecan or
fluorouracil/oxaliplatin. D and E were fluorouracil/iri-
notecan or fluorouracil/oxaliplatin from the outset. Only
the comparison of experimental arm C with control was
found to be superior using the outcome measure of over-
all survival. All comparison results are given in table 1.
Design of multi-stage re-analysis
We re-designed all four trials as though they had been run
in a two-stage design. To do this, parameters given in table
2 and based on the original trial protocols were used to
calculate the necessary number of control arm events eI for
the first stage using the n-stage program for Stata [10].
This program is also available from the authors upon
request. For trials ICON3, ICON4 and RE01, these calcu-
lations were based on using progression free survival
(PFS) as the intermediate outcome. In FOCUS, however,
it was decided that using PFS as an intermediate outcome
was not appropriate since the randomisation was to a
package of treatment both in the first line setting and at
progression. Hence, this trial re-analysis employs overall
survival as the outcome at both Stages 1 and 2. While the
targetted hazard ratio for the intermediate and final out-
come (for the alternative hypothesis) was specified as the
same value in most trials, in ICON4, the trial protocol had
specified a slightly lower hazard ratio for the final out-
come. This value was also used for this analysis. The lower
final stage significance level used for FOCUS reflects an
adjustment that was made for multiple comparisons due
to the number of arms considered in the trial.
An analysis on the intermediate endpoint was conducted
at the point where the target number of events for the
interim analysis had been 'accrued' in real time in the con-
trol group. Patients who had not 'entered' the trial at this
time point were excluded from the analysis. At this analy-
sis a hazard ratio for progression free survival was calcu-
lated and compared with a critical value for the hazard
ratio determined at the design stage. This critical hazard
Table 1: Treatment arm comparisons in FOCUS
Comparison Hazard ratio Confidence interval
regimen A vs B 0.905 0.788 – 1.039
regimen A vs C 0.837 0.728 – 0.962
regimen A vs D 0.969 0.846 – 1.110
regimen A vs E 0.925 0.807 – 1.061Page 2 of 10
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ratio on the intermediate outcome in Stage 1 under H0
and let  denote the normal deviate at one-sided sig-
nificance level α. Then, for a given probability p of being
allocated to the control arm and a required number of
control arm events 
The number of control arm events  targetted in this cal-
culation remains the same under both the null and alter-
native hypothesis. Thus, this critical value gives the lower
bound of a 1 -  % confidence interval around the haz-
ard ratio under H0 of no effect [11] (p.79). This means that
the one-sided 1 -  % confidence interval around 
will just include H0 at a power of %. Hence if an
observed hazard ratio is greater than this critical value, we
can reliable exclude an effect larger than under the null-
hypothesis at level . Please see the Additional File 1 for
a worked example. Therefore, if the hazard ratio was
smaller than this critical value a trial was counted as con-
tinuing to randomise further patients and if it was larger,
the trial was counted as 'stopped' in the sense that no fur-
ther randomisation would be conducted to that particular
experimental arm. A hazard ratio at the end of the trial
using overall survival was also calculated to obtain corre-
lation values between the test statistics on the intermedi-
ate outcome and the primary outcome. All hazard ratios
were calculated using the Cox regression model with treat-
ment the only covariate.
To calculate an error percentage estimate, 5000 trial data-
sets were created based on each original trial by taking
bootstrap samples with replacement from the trial dataset
[5] (p.82). If this scheme were employed without any fur-
ther adjustments, we would obtain a number of trials in
which the overall result does not match the original trial
result in terms of significance at the two-sided 5% level.
However, the question we wanted to answer was whether,
given a final result showing evidence of an effect of the
experimental treatment, this trial would have been cor-
rectly continued at the interim analysis using the interme-
diate outcome measure. Hence it was decided that we
would discard bootstrap samples in which the treatment
effect was non-significant at the 5% level. The same
applied to negative trials whereby we would discard if the
bootstrapped treatment effect was significant at this level.
Therefore, we employed a bootstrap sampling mechanism
which was conditional on the result of the final analysis.
On examining the mean of the resulting hazard ratios, we
find that across the 5000 datasets, this is very close to the
original trial result.
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Table 2: Parameter values for trial re-analysis based on trial protocols
Parameter ICON3 ICON4 RE01 FOCUS
Number of arms 2 2 2 5
Targeted hazard ratio intermediate outcome 0.75 0.75 0.71 0.73
Targeted hazard ratio final outcome 0.75 0.74 0.71 0.73
Power at 1st stage 95% 95% 95% 95%
Power at 2nd stage 90% 90% 90% 90%
Overall power (given by nstage.ado program) 87.4% 87.4% 87.4% 87.4%
Significance level at 2nd stage (one-sided) 2.5% 2.5% 2.5% 0.5%
Overall significance level (for stage 1 α = 0.1) 1.39% 1.39% 1.39% 0.35%
Allocation ratio (control:experimental) 2:1 1:1 1:1 2:1:1:1:1
Intermediate outcome (median survival) 1.5 years 10 months 2.5 months 9 months
Final outcome (median survival) 3 years 23 months 10 months 9 monthsPage 3 of 10
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trial was mimicked as described above and in addition, a
hazard ratio was calculated each time a new event was
observed.
All analyses were conducted in Stata version 9.2.
Results
Results of re-analysis using trial data only
In the first instance, all trials were re-analysed as described
in the methods to consider what would have happened
hypothetically if they had been designed as two-stage tri-
als. The results of this analysis are displayed in tables 3
and 4 as well as Figures 1 and 2. As can be observed, for
those trials/arms where the final result showed evidence
of a benefit (table 3), the trial/arm would have been con-
tinued at all stages. In the trials where the final analysis
showed no evidence of an effect (table 4), arms would
have been stopped at some of the first stage analyses but
not all. This is reflected in HR, the calculated hazard ratio
at each stage which varies over the course of the trial.
The figures shed further light on the developments over
time. In all cases, the solid line in the middle represents
the observed log hazard ratio with 95% confidence inter-
vals given as shaded areas around it. For trials ICON4,
ICON3 and RE01, log hazard ratios were calculated using
the PFS outcome as this was used as the intermediate out-
come in the re-design. For all arms in FOCUS, log hazard
ratios were calculated based on overall survival. Each of
the figures also includes the development of the log haz-
ard ratio critical value over time, displayed as a dashed
black line. The log hazard ratio in ICON4 and RE01 stays
below the critical value for the entirety of the trial. How-
ever, if we consider ICON3 for example, we can identify
why in 4 out of 5 analyses in the table, the trial would
have been carried on despite the final result showing no
evidence of a difference. The log hazard ratio is below the
critical value initially, then moves above it for a short
period of time after which it again moves below it. Only
very much later on in the trial does it return to above the
critical value again. The situation in FOCUS is similarly
ambiguous in the first stages of the trial. In all compari-
sons the observed estimate of the hazard ratio is very close
to the critical value at all times. This suggests that at best
there is a very small effect of the experimental treatment
over control, a long way away from the targetted hazard
ratio.
Results of re-analysis using bootstrapped data in 2 stages
Tables 5 to 8 give results for a re-analysis of all trials in 2
stages with the first two tables employing PFS as the inter-
mediate outcome. For comparisons between the control
and treatment arms for ICON3, the percentage error
relates to those trials where the treatment arm would have
been carried on. This is the case because the final trial
result showed no evidence of a difference. This error is
perhaps of not such great concern as we are continuing
arms which have no clear effect at the end of trial and thus
it can be argued that this is a 'conservative' error. For the
comparison in ICON4 for example though, percentage
error refers to the number of times when the treatment
arm would have been stopped at the stage 1 analysis even
though the final result was positive. This is an error of
greater concern to us since we are stopping a trial which
would have shown a benefit.
Our analyses show that if a treatment is successful on the
final outcome at the end of the trial, it has a very good
chance of 'jumping' the hurdle at the intermediate stages.
ICON4 and RE01 are both trials with a strong positive
outcome at the end of the trial and for these two trials, the
maximum error lies below 5% using PFS as the intermedi-
ate outcome and just above 6% using overall survival as
Table 3: Re-analysis of original trial data in trials showing evidence of an effect on the final outcome. 
one-sided significance ICON4 RE01 FOCUS A vs C
level at stage 1 δI HR decision δI HR decision δI HR decision
0.5 1 0.553 ✓ 1 0.683 ✓ 1 0.821 ✓
0.4 0.964 0.624 ✓ 0.964 0.729 ✓ 0.961 0.789 ✓
0.3 0.936 0.760 ✓ 0.924 0.660 ✓ 0.930 0.921 ✓
0.2 0.911 0.737 ✓ 0.902 0.649 ✓ 0.902 0.824 ✓
0.1 0.885 0.760 ✓ 0.874 0.674 ✓ 0.874 0.840 ✓
δI gives the cut-off hazard ratio for the intermediate outcome at a given one-sided significance level, HR gives the observed hazard ratio at that point 
in time, ✓ denotes that the trial would have been correctly carried on to the next stage, ✗ denotes that the trial would have been incorrectly 
stopped at stage 1Page 4 of 10
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FOCUS comparison A vs C are greater. However, the over-
all trial result was not clear in either the 'positive' or 'neg-
ative' direction, which is also illustrated in figure 1. The
results for ICON3 (table 6) also illustrate that since the
hazard ratio is not constant over time, the trend in the
error rate is also non-monotonic and counter-intuitive. In
this trial, as illustrated in figure 2, a very small effect size
can be observed which is close to but not at H0 and is also
near the critical value. Therefore, the bootstrap gives a
number of realisations which lie either side of the critical
value.
Tables 7 and 8 give the results for a bootstrap analysis
using the primary outcome for all stages of the trial. Inter-
estingly, results for the error rate are not improved (and
sometimes worse) when using this outcome. This suggests
that the error rate is not inflated by using a different out-
come at the intermediate analysis as compared to the final
analysis of the trial.
The correlation displayed is the correlation between the
test statistic at stage 1 and the end of the trial, i.e. the cor-
relation between the log hazard ratio for the intermediate
outcome at the time of that analysis and the log hazard
ratio for overall survival at the end of the trial. In the
FOCUS reanalysis, the outcome used at both stages is the
final outcome. As the results illustrate, the correlation is
surprisingly low for early analyses. The reason is that at a
high significance level, the number of control arm events
eI which are available for analysis is small and there is a
longer time interval between that analysis and the final
analysis. Furthermore, the analysis is based on a smaller
subset of patients.
Tables 6 and 8 additionally give information on the mean
time saved if a trial was stopped at an earlier stage for
those trials with a negative overall outcome. Mean time
saved was calculated by subtracting the mean time
required for a stage 1 analysis in the bootstrap runs from
the estimated time required for a standard parallel group
trial under the design assumptions. In this case, it was
assumed that had the trial only been conducted with a
final analysis on overall survival, this would have been
conducted at a significance level of 5% two-sided and
90% power. If an unsuccessful treatment is rejected at an
early stage, savings in trial time of 1.5 – 2.3 years can be
made.
Simultaneously considering the savings possible in total
trial time if a trial is correctly stopped at an earlier stage
and the error rate estimated for trials with a final analysis
showing evidence of a difference, we can draw some con-
clusions on the best placing of the stage 1 analysis. This
trade off between correctly and incorrectly stopping the
trial early suggests that ideally, the stage 1 analysis should
be placed at a significance level of 0.2 or 0.3. At this point,
the error rate in both the RE01 and ICON4 re-analyses is
negligible. At the same time, a saving in total trial time of
on average 1 and 2 years could have been made in FOCUS
and ICON3 respectively. However, more extensive studies
would need to be conducted to obtain the optimal timing
of the stage 1 analysis.
As the results in table 7 illustrate, FOCUS comparison A vs
C would have been stopped early in some cases even
though the overall trial result at the end of the trial could
be viewed as being at the 'margins' of statistical signifi-
cance. To circumvent this problem, it is anticipated that in
Table 4: Re-analysis of original trial data in trials showing no evidence of an effect on the final outcome. 
ICON3 FOCUS
one-sided significance A vs B A vs D A vs E A vs B A vs D A vs E
level at stage 1 δI HR decision δI HR decision
0.5 1 1.054 ✓ 1 0.876 0.841 1.008 ✗ ✗ ✓
0.4 0.964 0.965 ✗ 0.961 0.918 0.860 0.988 ✗ ✗ ✓
0.3 0.936 0.825 ✗ 0.930 0.892 0.750 0.902 ✗ ✗ ✗
0.2 0.911 0.806 ✗ 0.902 0.796 0.766 0.946 ✗ ✗ ✓
0.1 0.885 0.837 ✗ 0.874 0.887 0.879 0.937 ✓ ✓ ✓
δI gives the cut-off hazard ratio for the intermediate outcome at a given one-sided significance level, HR gives the observed hazard ratio at that point 
in time, ✓ denotes that the trial would have been correctly stopped at that stage, ✗ denotes that the trial would have been incorrectly carried on to 
the next stagePage 5 of 10
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dropped at an earlier stage will still be followed up and
the data analysed at a later stage. Table 9 illustrates what
the result of the final analysis would have been if the
FOCUS trial/arm had been stopped early and analysed at
a later date. This later analysis uses mature data from the
FOCUS trial in which nearly all patients had an event at
the point of analysis. However, only patients accrued by
the time of the relevant first stage analysis were included
in the final analysis. While the results for comparisons A
vs B, A vs D and A vs E are in line with the analysis given
in table 1, comparison A vs C is only marginally signifi-
cant if a late stage 1 analysis is conducted (HR of 0.86 if
the first stage analysis is conducted at a significance level
of 0.1).
Conclusion
Currently, according to FDA estimates [12], about 90% of
agents entering Phase I do not succeed at Phase III. This is
set against advances in our knowledge about pathways
connected to cancer development and metastases and
hence the availability of more agents for testing in clinical
trials. After passing Phase I/II, the success rate of cancer
Phase III trials is still only about 50%. However, if we for
example employ a multi-arm, multi-stage design with
four experimental regimens and one control, the proba-
bility of having at least one successful agent at the end of
the trial increases to 87%. This calculation assumes inde-
pendence of all experimental arms. Therefore, this type of
trial design uses resources more efficiently.
In this design we propose to target the event rate in the
control arm  rather than the number of events in all
arms combined. There are two reasons for this approach.
Firstly, an event rate different to that anticipated for the
trial overall could either arise due to a different underlying
event rate in all arms or due to a hazard ratio different to
that targeted initially. This level of ambiguity is removed
by using the control arm event rate as the deciding factor
eI1
Development of intermediate outcome hazard ratio over time in trials showing evidence of effect on primary outcomeFigure 1
Development of intermediate outcome hazard ratio over time in trials showing evidence of effect on primary 
outcome. 95% CIs for the hazard ratio (shaded area) and the critical value for assessing whether to continue randomising fur-
ther patients are given.Page 6 of 10
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than one experimental arm is recruited to, it is unlikely
that we shall observe the same hazard ratio in all compar-
isons, giving different total numbers of events for each
comparison. However, the calculation for the overall
number of events assumes the same event rate in all com-
parisons in the experimental arms.
We have demonstrated that using the MAMS designs, sig-
nificant savings can be made in terms of trial time if a
treatment does not prove to be effective over the course of
the trial. In this case, the trial re-analyses have demon-
strated that around 50% of all bootstrapped trials would
have been rejected at Stage 1, regardless of when this inter-
mediate stage was conducted. Greater savings can thus be
made if a MAMS trial is designed with three or more stages
as the probability of early rejection increases.
Trials with good evidence of an effect on overall survival
jump all of the intermediate hurdles with very high prob-
ability. For ICON4, this was found to be as high as 100%.
However, these methods do come at a cost. As the re-anal-
ysis of FOCUS comparison A/C has shown, trials or treat-
ment arms with very small treatment effects do risk being
discontinued earlier on during the trial. To alleviate this
problem in employing this design at the MRC CTU we fol-
low patients up further on discontinued arms while ran-
domisation to these arms is stopped. Thus, these arms will
also be analysed on the primary outcome at a later date
albeit with reduced power in some instances, depending
on the maturity of the data, so at least an estimate of the
effect size can be obtained.
Our re-analyses not only demonstrate the efficiency of the
MAMS design in general, but also explore the best timing
Development of intermediate outcome hazard ratio over time in trials showing no evidence of effect on primary outcomeFigure 2
Development of intermediate outcome hazard ratio over time in trials showing no evidence of effect on pri-
mary outcome. 95% CIs for the hazard ratio (shaded area) and the critical value for assessing whether to continue randomis-
ing further patients are given.Page 7 of 10
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stage is ideally placed at a significance level between 0.2
and 0.3 when the trade-off between the errors for correctly
and incorrectly stopping is considered. This was the point
at which the error rate in the RE01 re-analysis for example
became negligible, both for PFS and overall survival as the
intermediate endpoint. However, this is a practical recom-
mendation only and does not reflect an optimal design as
could be obtained from a simulation study.
A further observation in this study was the behaviour of
the correlation between the test statistics on the interme-
diate and primary outcome. If the first stage is conducted
early on with a very small number of control arm events,
this correlation coefficient is generally low, around 0.3. It
increases over time and reaches values in the range of 0.5
to 0.7 for a very late first stage analysis.
This type of analysis would ideally be done as a simula-
tion study, taking account of all possible trial scenarios.
However, we believe that the much simpler conditional
bootstrap approach that we employed is adequate. In this
analysis, we needed to be able to distinguish between the
error of stopping a trial early conditional on the final
result showing good evidence of an effect, and the error of
continuing a trial conditional on the final result showing
no evidence of an effect. Hence we used a conditional
bootstrap rather than the standard version since our inter-
est was in the error conditional on a particular final out-
come.
In this design no adjustment for multiple testing is made
to the type I error at the interim stages. There are a number
of reasons for this: i) early stopping for efficacy where the
issue of type I error is perhaps more acute, is not incorpo-
rated in the design, ii) the significance level at each stage
has a screening role only and is set close to 0.5 to ensure
an early first stage look and iii) the overall significance
level is bounded above by the significance level chosen for
the final stage. If desired, this final stage significance level
may be adjusted according to the number of experimental
arms considered. In fact, as the methods we present are for
stopping arms for lack of benefit it may be appropriate to
adjust the type II error for multiple comparisons at each
stage. However, in our experience this issue is typically not
considered.
When analysing the trial at the intermediate stages, power
may be increased by including covariates. Since the early
stages will contain few patients, the trial population
across the arms is more likely to be unbalanced in terms
of potentially confounding covariates such as age. Includ-
ing these known influential covariates in the analysis may
increase the robustness of the results.
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Table 5: Re-analysis over two stages of trials with final result 
showing evidence of a difference employing PFS as an 
intermediate outcome. 
ICON4 RE01
one-sided sig. eI % ρ eI % ρ
level at stage 1 err. err.
0.5 75 0.04 0.27 53 3.18 0.27
0.4 97 0.20 0.29 69 4.58 0.31
0.3 125 0.03 0.36 88 1.08 0.34
0.2 162 0.26 0.39 114 0.26 0.39
0.1 221 0.12 0.44 155 0.46 0.46
eI gives the number of control arm events for the significance level at 
stage 1, % err. gives the percentage of trials out of 5000 which were 
stopped, ρ gives the correlation between the test statistic at stage 1 
on the intermediate outcome and at the final analysis on the primary 
outcome
Table 6: Re-analysis over two stages of trials with final result 
showing no evidence of a difference employing PFS as an 
intermediate outcome. 
ICON3
one-sided sig. eI % ρ mean time
level at stage 1 err. saved (yrs)
0.5 116 43.40 0.27 2.33
0.4 152 46.40 0.32 2.17
0.3 194 65.64 0.35 2.02
0.2 250 87.28 0.39 1.86
0.1 339 69.02 0.47 1.53
For details see legend of table 5Page 8 of 10
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Table 7: Re-analysis over two stages of trials with final result showing evidence of a difference using overall survival as intermediate 
endpoint.
ICON4 RE01 FOCUS: A vs C
one-sided sig. eI % ρ eI % ρ eI % ρ
level at stage 1 err. err. err.
0.5 75 0.0 0.32 53 6.32 0.44 97 9.42 0.28
0.4 97 0.0 0.46 69 3.84 0.50 125 8.4 0.30
0.3 125 0.0 0.56 88 0.62 0.57 161 32.54 0.38
0.2 162 0.0 0.70 114 0.68 0.68 206 15.44 0.42
0.1 221 0.1 0.76 155 0.04 0.88 280 16.12 0.50
For details see legend of table 5.
Table 8: Re-analysis over two stages of trials with final result showing no evidence of a difference using overall survival as intermediate 
endpoint.
ICON3 FOCUS
A vs B A vs D A vs E
one-sided sig. eI % ρ time eI % ρ % ρ % ρ mean time
level at stage 1 err. saved (yrs) Err. err. err. saved (yrs)
0.5 116 61.44 0.31 1.89 97 68.32 0.31 82.34 0.36 43.04 0.27 1.51
0.4 152 42.44 0.36 1.67 125 58.32 0.36 81.5 0.39 50.88 0.29 1.32
0.3 194 45.4 0.41 1.48 161 56.92 0.40 90.82 0.43 57.76 0.35 1.07
0.2 250 56.46 0.47 1.25 206 77.98 0.43 88.08 0.50 34.96 0.40 0.83
0.1 339 52.56 0.54 0.83 280 35.4 0.52 44.44 0.62 16.98 0.50 0.34
For details see legend of table 5
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Appendix: worked example. An appendix containing a worked example 
for the calculation of the control arm number of events and critical hazard 
ratio.
Click here for file
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Table 9: FOCUS results of final analysis after early stopping at stage 1. 
one-sided sig. level A vs B A vs C A vs D A vs E Power for
at recruitment stop HR 95% CI HR 95% CI HR 95% CI HR 95% CI final analysis
0.5 0.93 (0.76–1.13) 0.88 (0.72–1.08) 0.96 (0.78–1.17) 1.03 (0.85–1.26) 90%
0.4 0.94 (0.78–1.14) 0.87 (0.72–1.05) 0.97 (0.81–1.18) 1.04 (0.86–1.25) > 90%
0.3 0.89 (0.74–1.06) 0.88 (0.73–1.05) 0.94 (0.79–1.13) 0.97 (0.81–1.16) > 90%
0.2 0.92 (0.77–1.09) 0.93 (0.78–1.10) 0.99 (0.84–1.17) 1.03 (0.87–1.22) > 90%
0.1 0.89 (0.76–1.04) 0.86 (0.73–1.00) 0.99 (0.85–1.15) 0.97 (0.83–1.13) > 90%
n/a – actual analysis 0.91 (0.81–1.06) 0.84 (0.73–0.96) 0.97 (0.85–1.11) 0.93 (0.81–1.06) n/a
This analysis was carried out on mature data for the primary endpoint including only those patients recruited up to the time of the first stage 
analysis. HR – hazard ratio on primary outcome (overall survival), CI – 95% confidence interval around the hazard ratio, Power for final analysis – 
this was calculated for a targetted alternative of 0.73 (as specified in the protocol)Page 10 of 10
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